IMV-102 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving IMV-102 Growth

1. Potential to Eliminate Complex CAR-T Manufacturing

A major growth driver for IMV-102 is it's in vivo CAR-T approach, which seeks to bypass leukapheresis, centralized manufacturing, and lengthy production timelines required by conventional CAR-T therapies.

Current BCMA CAR-T therapies such as Carvykti and Abecma require individualized manufacturing that can take several weeks. IMV-102 aims to generate CAR-T cells directly within the patient, potentially reducing treatment delays and improving accessibility. According to Immunofoco, the iMAGIC platform was specifically designed to address scalability and manufacturing limitations associated with traditional CAR-T therapy.

2. Validation of the BCMA Target in Multiple Myeloma

BCMA has become one of the most validated targets in multiple myeloma. Approved BCMA-directed therapies have demonstrated deep and durable responses in heavily pretreated patients.

For example:

• Carvykti achieved overall response rates exceeding 95% in pivotal studies.
• Abecma demonstrated meaningful survival benefits in relapsed/refractory multiple myeloma.

The success of these therapies significantly de-risks the biological rationale for IMV-102 because it utilizes the same BCMA target while attempting to improve delivery and manufacturing efficiency.

3. Large and Growing Multiple Myeloma Market

Multiple myeloma remains an incurable plasma-cell malignancy despite major therapeutic advances.

According to published epidemiological studies:

• More than 180,000 new multiple myeloma cases are diagnosed globally each year.
• Patients typically receive multiple lines of therapy and eventually develop refractory disease.

As patients progress through existing treatments, demand for highly effective BCMA-directed therapies continues to increase. IMV-102 could potentially participate in this expanding treatment landscape if clinical efficacy is confirmed.

4. Potential Cost and Access Advantages Over Conventional CAR-T

Commercial adoption of CAR-T therapy is often constrained by:

• Manufacturing complexity.
• Specialized treatment centers.
• High treatment costs.
• Limited production capacity.

An effective in vivo CAR-T approach could significantly lower manufacturing costs and increase patient access. This represents one of the most important commercial opportunities for the entire in vivo cell therapy field. If IMV-102 can demonstrate efficacy comparable to approved BCMA CAR-T therapies while simplifying treatment logistics, it may achieve meaningful competitive differentiation.

IMV-102 Recent Developments

In April 2026, Immunofoco announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies.

"IMV-102 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of IMV-102 for potential indication like Multiple myeloma in the 7MM. A detailed picture of IMV-102's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IMV-102 for potential indications. The IMV-102 market report provides insights about IMV-102's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMV-102 performance, future market assessments inclusive of the IMV-102 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMV-102 sales forecasts, along with factors driving its market.

IMV-102 Drug Summary

IMV-102 is an investigational in vivo BCMA-targeted CAR-T therapy being developed by Immunofoco for the treatment of relapsed/refractory multiple myeloma and potentially other B-cell-mediated diseases. Unlike conventional ex vivo CAR-T therapies that require collection, genetic modification, and reinfusion of a patient's T cells, IMV-102 utilizes Immunofoco's proprietary iMAGIC platform, a lentiviral vector-based system designed to generate BCMA-directed CAR-T cells directly within the patient's body. The therapy selectively targets and transduces T cells in vivo, enabling them to recognize and eliminate BCMA-expressing malignant plasma cells while potentially reducing the manufacturing complexity, treatment delays, and costs associated with traditional CAR-T products. Preclinical studies have demonstrated efficient and selective T-cell transduction, potent cytotoxic activity against BCMA-positive multiple myeloma cells, durable tumor control in xenograft models, and a favorable safety profile with minimal off-target effects. IMV-102 has advanced into early clinical development, including an investigator-initiated study in patients with relapsed/refractory multiple myeloma, where its safety, pharmacokinetics, and preliminary antitumor efficacy are being evaluated. The report provides IMV-102's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IMV-102 Market Report

The report provides insights into:

• A comprehensive product overview including the IMV-102 MoA, description, dosage and administration, research and development activities in potential indication like Multiple myeloma.
• Elaborated details on IMV-102 regulatory milestones and other development activities have been provided in IMV-102 market report.
• The report also highlights IMV-102's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IMV-102 market report also covers the patents information, generic entry and impact on cost cut.
• The IMV-102 market report contains current and forecasted IMV-102 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMV-102 market report also features the SWOT analysis with analyst views for IMV-102 in potential indications.

Methodology:

The IMV-102 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMV-102 Analytical Perspective by DelveInsight

• In-depth IMV-102 Market Assessment

This IMV-102 sales market forecast report provides a detailed market assessment of IMV-102 for potential indication like Multiple myeloma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMV-102 sales data uptil 2034.

• IMV-102 Clinical Assessment

The IMV-102 market report provides the clinical trials information of IMV-102 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMV-102 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMV-102 Market Potential & Revenue Forecast

• Projected market size for the IMV-102 and its key indications
• Estimated IMV-102 sales potential (IMV-102 peak sales forecasts)
• IMV-102 Pricing strategies and reimbursement landscape

IMV-102 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IMV-102 Market positioning compared to existing treatments
• IMV-102 Strengths & weaknesses relative to competitors

IMV-102 Regulatory & Commercial Milestones

• IMV-102 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IMV-102 Clinical Differentiation

• IMV-102 Efficacy & safety advantages over existing drugs
• IMV-102 Unique selling points

IMV-102 Market Report Highlights

• In the coming years, the IMV-102 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMV-102 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMV-102's dominance.
• Other emerging products for Multiple myeloma are expected to give tough market competition to IMV-102 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMV-102 in potential indications.
• Analyse IMV-102 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMV-102 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMV-102 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of IMV-102? How strong is IMV-102's clinical and commercial performance?
• What is IMV-102's clinical trial status in each individual indications such as Multiple myeloma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMV-102 Manufacturers?
• What are the key designations that have been granted to IMV-102 for potential indications? How are they going to impact IMV-102's penetration in various geographies?
• What is the current and forecasted IMV-102 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMV-102 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMV-102 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IMV-102? What is the duration of therapy and what are the geographical variations in cost per patient?